Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Earnings for Onconova Therapeutics, Inc. (ONTX)
Earnings in 2023 (TTM): $-18,948,000
According to Onconova Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-18,948,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Onconova Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-18,948,000 | $-18,948,000 |
| 2022 | $-18,964,000 | $-18,301,000 |
| 2021 | $-16,163,000 | $-15,828,000 |
| 2020 | $-25,153,000 | $-25,157,000 |
| 2019 | $-21,493,000 | $-21,503,000 |
| 2018 | $-20,534,000 | $-20,573,000 |
| 2017 | $-24,079,000 | $-24,092,000 |
| 2016 | $-19,653,000 | $-19,667,000 |
| 2015 | $-24,007,000 | $-23,979,000 |
| 2014 | $-63,776,000 | $-63,682,000 |
| 2013 | $-62,121,000 | $-62,543,000 |
| 2012 | $-29,912,000 | $-29,912,000 |
| 2011 | $-26,294,000 | $-26,294,000 |